Etravirine

證據等級: L5

預測適應症: 10 個

Etravirine: From HIV-1 Infection (NNRTI-Class) to Congenital HIV Infection (Perinatal Transmission Prevention)

One-Sentence Summary

Etravirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) used for HIV-1 infection, particularly in NNRTI-experienced adults. Among the 10 TxGNN-predicted indications in this evidence pack, most (including the top-ranked "feline acquired immunodeficiency syndrome") show no credible mechanistic support and are flagged as likely model noise. The one candidate with real evidentiary weight — Congenital HIV Infection / perinatal transmission prevention — is supported by 13 clinical trials (including Phase 3 regimen studies and pregnancy-specific pharmacokinetic trials) and 1 publication, reflecting a natural life-cycle extension of etravirine's existing HIV-1 use rather than a truly novel mechanism.

⚠️ Note: The evidence pack's top-ranked prediction by raw TxGNN score is "feline acquired immunodeficiency syndrome" (a veterinary/cross-species entity) and "simian immunodeficiency virus infection," both scored L5/Hold with explicit rationale stating there is no mechanistic support. This report focuses instead on the highest-quality, evidence-backed candidate (rank 5, L2) rather than the raw top-score entry, to avoid presenting a misleading headline.

Quick Overview

Item	Content
Original Indication	HIV-1 infection, NNRTI-resistance setting (structured field is a data gap; drawn from repurposing_rationale text)
Predicted New Indication	Congenital HIV Infection (perinatal/vertical transmission prevention)
TxGNN Prediction Score	99.79% (rank 3016 of model output)
Evidence Level	L2
Germany Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action (MOA) data is not available for etravirine in this evidence pack (data gap DG002). Based on the information available, etravirine is a diarylpyrimidine NNRTI approved for HIV-1 infection, and its core indication — treatment of HIV-1 in patients with documented NNRTI resistance — is well established. Congenital/perinatal HIV infection is not a distinct disease mechanism but part of the same HIV-1 disease spectrum, transmitted from mother to child; preventing it relies on suppressing maternal HIV-1 viral load with the same class of antiretroviral agents used in adult treatment.

This is reflected directly in the evidence: several Phase 3 trials in this pack (e.g., NCT00855335, NCT00042289) specifically study antiretroviral pharmacokinetics — including etravirine — in HIV-1-infected pregnant women, and one Phase 1 trial (NCT04630002) directly evaluates etravirine drug-drug interactions in combination therapy. This indicates the "new indication" is less a mechanistic leap and more an extension of etravirine's known use into the perinatal population, which is why it is the only candidate in this pack reaching evidence level L2.

By contrast, the model's top three ranked predictions — feline AIDS, simian immunodeficiency virus infection, and a rare neurodevelopmental disorder — lack any plausible biological link to etravirine's NNRTI mechanism, as explicitly stated in the pack's own rationale text (cross-species/cross-family enzyme mismatch, or no known pathway overlap at all). These are treated as likely model artifacts rather than genuine repurposing signals.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00855335	Phase 3	Completed	77	PK of darunavir, ritonavir, etravirine, and rilpivirine specifically in HIV-1-infected pregnant women
NCT00042289	Phase 4	Completed	1578	IMPAACT P1026s — PK of antiretrovirals (incl. etravirine-class agents) during pregnancy/postpartum
NCT04630002	Phase 1	Completed	54	Drug-drug interaction study of darunavir/ritonavir and/or etravirine with GSK3640254
NCT01199731	Phase 2b	Terminated	30	GSK2248761 dose-selection study using open-label etravirine 200mg BID as control arm
NCT07412977	N/A	Not yet recruiting	5160	VIROPREG — French cohort on viral infections (incl. HIV) and antiviral treatment impact on pregnancy/mother-to-child transmission
NCT02951052	Phase 3	Active, not recruiting	618	ATLAS — switching virologically suppressed HIV-1 adults to long-acting cabotegravir + rilpivirine
NCT02429791	Phase 3	Completed	510	Switching to dolutegravir + rilpivirine from INI-/NNRTI-/PI-based regimen in suppressed HIV-1 adults
NCT02422797	Phase 3	Completed	518	Same design as above, second cohort
NCT03299049	Phase 3b	Active, not recruiting	1049	ATLAS-2M — long-acting cabotegravir + rilpivirine dosed Q8W vs Q4W
NCT02938520	Phase 3	Active, not recruiting	631	FLAIR — long-acting IM cabotegravir/rilpivirine maintenance after switch from INI regimen

Excluded from this table: NCT04273165 (Friedreich Ataxia trial — confirmed database mismatch, unrelated to HIV) and NCT01458132 (GSK drug-exposure registry, etravirine involvement unconfirmed).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
20587860	2010	Cohort/Case series	Antiviral Therapy	Two case reports on use of darunavir and etravirine (± raltegravir) in pregnancy for highly treatment-experienced HIV patients

Other TxGNN Predictions (Screened Out)

For transparency, the remaining 9 predicted indications in this evidence pack are summarized below. All were assessed as insufficiently supported for further action:

Rank	Disease	Evidence Level	Decision	Reason
1	Feline acquired immunodeficiency syndrome	L5	Hold	Cross-species mismatch; FIV reverse transcriptase not a designed target
2	Simian immunodeficiency virus infection	L4	Hold	Only indirect in vitro nanoparticle-delivery literature; no direct SIV-RT inhibition data
3	Rare neurodevelopmental disorder (ataxic gait/absent speech)	L5	Hold	No mechanistic link; likely model noise
4	AIDS related complex	L3	Research Question	Within core HIV-1 disease spectrum; evidence indirect (PROTEKT trial relevance unconfirmed)
6	Fibroma of prostate	L5	Hold	No mechanistic link
7	Brenner tumor	L5	Hold	No mechanistic link
8	Benign reproductive system neoplasm	L5	Hold	Non-specific disease category, no biological hypothesis
9	Benign prostate phyllodes tumor	L5	Hold	No mechanistic link
10	Obsolete familial combined hyperlipidemia	L5	Hold	Reflects a known NNRTI side effect (dyslipidemia), not a treatment use; disease class is obsolete

Germany Market Information

Etravirine currently has no marketing authorization records in the German dataset (taiwan_regulatory.total_licenses = 0). No product, dosage form, or approved indication text is available.

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug-drug interaction data are not available in this evidence pack (flagged as Blocking data gap DG001 — TFDA label warnings/contraindications).

Conclusion and Next Steps

Decision: Hold

Rationale: The most credible predicted indication — congenital/perinatal HIV infection — is mechanistically coherent (same virus, same drug class, extension into pregnancy) and supported by Phase 3 and pregnancy-specific PK trials, reaching evidence level L2. However, the drug currently has zero marketing authorizations in Germany, and a Blocking data gap (missing TFDA label warnings/contraindications) prevents completion of the S1 safety screen. The remaining 9 predicted indications lack credible mechanistic or clinical support and should not be pursued.

To proceed, the following is needed:

TFDA product label (warnings, contraindications) — currently a Blocking gap (DG001)
Original mechanism of action documentation from DrugBank — currently a High-severity gap (DG002)
Confirmation of etravirine's original approved indication(s), which are currently unpopulated in this record
If pursuing the perinatal-transmission indication: a dedicated efficacy/safety study of etravirine specifically for prevention of vertical HIV transmission, since existing trials (PK studies, regimen-switch trials) do not directly test this endpoint
Clarification of German/EU market access pathway, given the drug is currently unmarketed
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.